Differential Target Multiplexed (DTM) spinal cord stimulation (SCS) endurance therapy provides meaningful pain relief according to three-month data from the DTM-LE trial—the findings of which were recently released at the North American Neuromodulation Society’s (NANS) 25th annual meeting (13–15 January 2022, Florida, USA).
The on-label, prospective, multicentre study showed that Medtronic’s DTM SCS endurance therapy— a modified, lower-energy variation of the company’s DMT SCS therapy for chronic overall, back or leg pain—offered meaningful pain relief to patients.
At three months, patients treated with DTM SCS endurance therapy reported meaningful pain relief as measured by a 3.9cm reduction in overall pain on the 10cm Visual Analog Scale. Patients also reported an average 4.3cm decrease in back pain, and an average 5cm decrease in leg pain.
A little over two-thirds (69%) of patients improved to a less disabled category as measured by the Oswestry Disability Index, with 63% having minimal or moderate disability at three months compared to just 16% at baseline. In addition, 75% of patients were very satisfied or somewhat satisfied with their therapy at three months.
According to Medtronic, modelling based on the three-month data also shows that DTM SCS endurance therapy enables between 5.5–7.5 years device longevity when programmed on the Vanta recharge-free neurostimulator. And, for those in need of a rechargeable device, DTM SCS endurance therapy programmed on the Intellis rechargeable neurostimulator allows either rapid recharge (five minutes per day) or recharges of approximately one hour every 12 days.
Kasra Amirdelfan, director of clinical research at IPM Medical Group and principal investigator on the DTM-LE trial, said: “These three-month results are highly encouraging, as they demonstrate that the DTM SCS endurance therapy may be able to provide effective pain relief while dosing at lower energy than other SCS waveforms. This may improve device longevity and offers validation of therapy for the patients who would need it.”
Charlie Covert, vice president and general manager of pain therapies at Medtronic, added: “Every patient with chronic pain has their own unique needs, and Medtronic is committed to offering solutions that personalise care for our patients.
“For many, especially those who need or prefer a recharge-free SCS solution, our new DTM SCS endurance therapy offers meaningful clinical benefits by reducing pain, improving quality of life, and offering meaningful device longevity.”
Enrolled patients will have additional follow-up assessments at six and 12 months.